The fund invests in equity securities of companies substantially in the same proportion as its underlying index. These securities are classified as life sciences companies and other companies with significant business activities in the US marijuana and hemp industries. Rebalanced quarterly, the portfolio is market-cap-weighted with 10% maximum capping for each constituent.